國家衛生研究院 NHRI:Item 3990099045/1258

NHRI > Institute of Biotechnology and Pharmaceutical Research > Hsing-Pang Hsieh > Periodical Articles > Item 3990099045/1258

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/1258

Title:	Antitubulin agents for the treatment of cancer - a medicinal chemistry update
Authors:	Mahindroo, N;Liou, JP;Chang, JY;Hsieh, HP
Contributors:	Division of Biotechnology and Pharmaceutical Research
Abstract:	The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.
Keywords:	Medicine, Legal;Pharmacology & Pharmacy
Date:	2006-05
Relation:	Expert Opinion on Therapeutic Patents. 2006 May;16(5):647-691.
Link to:	http://dx.doi.org/10.1517/13543776.16.5.647
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1354-3776&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000237502300005
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33646551448
Appears in Collections:	[Hsing-Pang Hsieh] Periodical Articles [Jang-Yang Chang] Periodical Articles

Files in This Item:

File	Description	Size	Format
000237502300005.pdf		547Kb	Adobe PDF	365	View/Open

Loading...